Cite
Second-Line Combination Chemotherapy with Docetaxel for Cisplatin-Pretreated Refractory Metastatic Esophageal Cancer: A Preliminary Report of Initial Experience.
MLA
Tanaka, Toshiaki, et al. “Second-Line Combination Chemotherapy with Docetaxel for Cisplatin-Pretreated Refractory Metastatic Esophageal Cancer: A Preliminary Report of Initial Experience.” Chemotherapy (0009-3157), vol. 53, no. 6, Nov. 2007, pp. 449–53. EBSCOhost, https://doi.org/10.1159/000110018.
APA
Tanaka, T., Fujita, H., Sueyoshi, S., Tanaka, Y., Sasahara, H., Mori, N., Nagano, T., Yamana, H., & Shirouzu, K. (2007). Second-Line Combination Chemotherapy with Docetaxel for Cisplatin-Pretreated Refractory Metastatic Esophageal Cancer: A Preliminary Report of Initial Experience. Chemotherapy (0009-3157), 53(6), 449–453. https://doi.org/10.1159/000110018
Chicago
Tanaka, Toshiaki, Hiromasa Fujita, Susumu Sueyoshi, Yuichi Tanaka, Hiroko Sasahara, Naoki Mori, Tsuyoshi Nagano, Hideaki Yamana, and Kazuo Shirouzu. 2007. “Second-Line Combination Chemotherapy with Docetaxel for Cisplatin-Pretreated Refractory Metastatic Esophageal Cancer: A Preliminary Report of Initial Experience.” Chemotherapy (0009-3157) 53 (6): 449–53. doi:10.1159/000110018.